CD16+ as predictive marker for early relapse in aggressive B-NHL/DLBCL patients.
Humans
Receptors, IgG
/ metabolism
Prognosis
Killer Cells, Natural
/ metabolism
Monocytes
/ metabolism
Biomarkers, Tumor
Male
Female
Neoplasm Recurrence, Local
/ pathology
GPI-Linked Proteins
/ metabolism
Lymphoma, B-Cell
/ metabolism
Middle Aged
T-Lymphocytes
/ metabolism
Antibody-Dependent Cell Cytotoxicity
Aged
Kaplan-Meier Estimate
CD16+ T cell
CD16+ monocyte
aggressive B-NHL (non-Hodgkin B cell lymphoma)
antibody-dependent cellular cytotoxicity (ADCC)
diffuse large B cell lymphoma (DLBCL)
rituximab
Journal
Molecular cancer
ISSN: 1476-4598
Titre abrégé: Mol Cancer
Pays: England
ID NLM: 101147698
Informations de publication
Date de publication:
28 Sep 2024
28 Sep 2024
Historique:
received:
20
06
2024
accepted:
14
09
2024
medline:
29
9
2024
pubmed:
29
9
2024
entrez:
28
9
2024
Statut:
epublish
Résumé
Assessing the prognosis of patients with aggressive non-Hodgkin B cell lymphoma mainly relies on a clinical risk score (IPI). Standard first-line therapies are based on a chemo-immunotherapy with rituximab, which mediates CD16-dependent antibody-dependent cellular cytotoxicity (ADCC). We phenotypically and functionally analyzed blood samples from 46 patients focusing on CD16+ NK cells, CD16+ T cells and CD16+ monocytes. Kaplan-Meier survival curves show a superior progression-free survival (PFS) for patients having more than 1.6% CD16+ T cells (p = 0.02; HR = 0.13 (0.007-0.67)) but an inferior PFS having more than 10.0% CD16+ monocytes (p = 0.0003; HR = 16.0 (3.1-291.9)) at diagnosis. Surprisingly, no correlation with NK cells was found. The increased risk of relapse in the presence of > 10.0% CD16+ monocytes is reversed by the simultaneous occurrence of > 1.6% CD16+ T cells. The unexpectedly strong protective function of CD16+ T cells could be explained by their high antibody-dependent cellular cytotoxicity as quantified by real-time killing assays and single-cell imaging. The combined analysis of CD16+ monocytes (> 10%) and CD16+ T cells (< 1.6%) provided a strong model with a Harrell's C index of 0.80 and a very strong power of 0.996 even with our sample size of 46 patients. CD16 assessment in the initial blood analysis is thus a precise marker for early relapse prediction.
Identifiants
pubmed: 39342291
doi: 10.1186/s12943-024-02123-7
pii: 10.1186/s12943-024-02123-7
doi:
Substances chimiques
Receptors, IgG
0
FCGR3B protein, human
0
Biomarkers, Tumor
0
GPI-Linked Proteins
0
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
210Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : 4D-CARLY - UL 316/9-1 and SFB/CRC1292, Project-ID 318346496
Organisme : Deutsche Forschungsgemeinschaft
ID : 4D-CARLY - UL 316/9-1 and SFB/CRC1292, Project-ID 318346496
Organisme : Deutsche Forschungsgemeinschaft
ID : SFB1027, A11 and SFB894, A1
Organisme : Deutsche Krebshilfe
ID : #70114180 and #70115200
Organisme : Bundesministerium für Bildung und Forschung
ID : 031LO133
Informations de copyright
© 2024. The Author(s).
Références
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.
doi: 10.1056/NEJMoa011795
pubmed: 11807147
Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) group. Lancet Oncol. 2006;7:379–91.
doi: 10.1016/S1470-2045(06)70664-7
pubmed: 16648042
Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trneny M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, et al. Polatuzumab Vedotin in previously untreated diffuse large B-Cell lymphoma. N Engl J Med. 2022;386:351–63.
doi: 10.1056/NEJMoa2115304
pubmed: 34904799
Sehn LH, Salles G. Diffuse large B-Cell lymphoma. N Engl J Med. 2021;384:842–58.
doi: 10.1056/NEJMra2027612
pubmed: 33657296
pmcid: 8377611
International Non-Hodgkin’s Lymphoma Prognostic Factors P. A predictive model for aggressive non-hodgkin’s lymphoma. N Engl J Med. 1993;329:987–94.
doi: 10.1056/NEJM199309303291402
Jelicic J, Larsen TS, Maksimovic M, Trajkovic G. Available prognostic models for risk stratification of diffuse large B cell lymphoma patients: a systematic review. Crit Rev Oncol Hematol. 2019;133:1–16.
doi: 10.1016/j.critrevonc.2018.10.006
pubmed: 30661646
Backes CS, Friedmann KS, Mang S, Knorck A, Hoth M, Kummerow C. Natural killer cells induce distinct modes of cancer cell death: discrimination, quantification, and modulation of apoptosis, necrosis, and mixed forms. J Biol Chem. 2018;293:16348–63.
doi: 10.1074/jbc.RA118.004549
pubmed: 30190323
pmcid: 6200954
Gu L, Li H, Chen L, Ma X, Li X, Gao Y, Zhang Y, Xie Y, Zhang X. Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis. Oncotarget. 2016;7:31926–42.
doi: 10.18632/oncotarget.7876
pubmed: 26942464
pmcid: 5077986
Wen S, Chen N, Peng J, Ling W, Fang Q, Yin SF, He X, Qiu M, Hu Y. Peripheral monocyte counts predict the clinical outcome for patients with colorectal cancer: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2019;31:1313–21.
doi: 10.1097/MEG.0000000000001553
pubmed: 31567616
Li YL, Gu KS, Pan YY, Jiao Y, Zhai ZM. Peripheral blood lymphocyte/monocyte ratio at the time of first relapse predicts outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. BMC Cancer. 2014;14:341.
doi: 10.1186/1471-2407-14-341
pubmed: 24884604
pmcid: 4033684
Maurer MJ, Jais JP, Ghesquieres H, Witzig TE, Hong F, Haioun C, Thompson CA, Thieblemont C, Micallef IN, Porrata LF, et al. Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. Am J Hematol. 2016;91:179–84.
doi: 10.1002/ajh.24223
pubmed: 26492520
Tadmor T, Bari A, Sacchi S, Marcheselli L, Liardo EV, Avivi I, Benyamini N, Attias D, Pozzi S, Cox MC, et al. Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era. Haematologica. 2014;99:125–30.
doi: 10.3324/haematol.2013.088161
pubmed: 23935023
pmcid: 4007925
Rambaldi A, Boschini C, Gritti G, Delaini F, Oldani E, Rossi A, Barbui AM, Caracciolo D, Ladetto M, Gueli A, et al. The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when Rituximab is added to chemotherapy. Am J Hematol. 2013;88:1062–7.
doi: 10.1002/ajh.23566
pubmed: 23940056
Han X, Ruan J, Zhang W, Zhou D, Xu D, Pei Q, Ouyang M, Zuo M. Prognostic implication of leucocyte subpopulations in diffuse large B-cell lymphoma. Oncotarget 2017;8:47790–47800. https://doi.org/10.18632/oncotarget.17830
Le Gallou S, Lhomme F, Irish JM, Mingam A, Pangault C, Monvoisin C, Ferrant J, Azzaoui I, Rossille D, Bouabdallah K, et al. Nonclassical monocytes are Prone to migrate into tumor in diffuse large B-Cell lymphoma. Front Immunol. 2021;12:755623.
doi: 10.3389/fimmu.2021.755623
pubmed: 34975843
pmcid: 8716558
Saura-Esteller J, de Jong M, King LA, Ensing E, Winograd B, de Gruijl TD, Parren P, van der Vliet HJ. Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future. Front Immunol. 2022;13:915837.
doi: 10.3389/fimmu.2022.915837
pubmed: 35784326
pmcid: 9245381